AlphAIAlphAI — Financial news for AI agents
finanznachrichten.deSEP 162 min read$BIVI

RedChip Companies, Inc.: Join BioVie's Exclusive Live Investor Webinar: Inside the ADDRESS-LC Phase 2 Results

BioVie (NASDAQ:BIVI) will host an investor webinar on September 23, 2026, to discuss Phase 2 results of its drug bezisterim for Long COVID. CEO Cuong Do will present findings showing potential across key symptoms and discuss implications for neurological disorders. The company believes positive results could support bezisterim's development for multiple CNS conditions.

Original reporting
finanznachrichten.de
Published Sep 16, 2026, 1:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 16, 2026, 2:34 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefTechnology
Primary signal
$BIVI
Bullish
high confidence
Mentioned
$BIVI
Relevance
8/10
AlphAI data visualization · based on finanznachrichten.de
Decision brief

The 30-second read

$BIVIBullishMed
01

Why it matters

The data could catalyze a short‑term rally, but long‑term valuation depends on subsequent Phase 3 results and FDA review.

02

Market read

First disclosure of Phase 2 results for a micro‑cap biotech, likely to move BIVI stock and influence related neuro‑inflammation stocks.

03

What to watch

Regulatory timeline and competition from other Long COVID candidates.

Relevance 8/10Novelty 8/10Timing: today

Background

The release announces a live investor webinar and presents the first public readout of BioVie's Phase 2 trial for bezisterim.

Company-level read

Ticker impact

$BIVIBullishHigh confidence
Context

BioVie disclosed Phase 2 ADDRESS-LC trial results, with 21 of 22 endpoints favoring bezisterim for Long COVID.

Expected impact

Potential upside of 10‑15% over the next weeks if data holds up.

Evidence & confidence

Phase 2 success in a micro‑cap biotech often triggers speculative buying ahead of further trials.

Market effects

Sector

Positive data may lift other neuro‑inflammation biotech peers.

Regional

Limited to US and biotech‑focused investors.

Global

Adds to broader interest in Long COVID therapeutics.

Counterpoint

What could challenge this read

Phase 2 success does not guarantee Phase 3 outcomes; risk of over‑optimism.

Key entities

  • company
    BioVie Inc.

    Clinical‑stage biopharma developing bezisterim for neuro‑inflammatory conditions.

  • service_provider
    RedChip Companies, Inc.

    Investor‑relations firm hosting the webinar.

Read at source← All news

Related articles

OCT 26
$SPCXHighAI 8/10

MARKETS LIVE: Wall Street in the green as investors weigh Anthropic IPO filing

SpaceX committed to a $40B lease for Nvidia chips. Xencor shares rose 20% on positive drug trial results. Surgery Partners surged 46% after a $5.7B acquisition deal. Tesla gained 6% following a Barclays upgrade. Verizon raised 2026 guidance after strong customer additions. Anthropic filed for IPO, with concerns raised about its valuation and spending. FTSE 100 gained 0.7%. Big Tech earnings and Fed decision are key focuses this week.

proactiveinvestors.com3 min
OCT 24
$BIVIMedAI 8/10

From Private Credit to Fusion Power: New to The Street Show #777 Premieres Tonight on Bloomberg Television

New to The Street Show #777 features executives from Stewards Investment Capital, BioVie (NASDAQ:BIVI), FreeCast (NASDAQ:CAST), and American Fusion (OTCQB:AMFN). BioVie reports positive long COVID and Parkinson's trial results. FreeCast discusses its media monetization technology. American Fusion presents its fusion power technology. The show airs on Bloomberg Television and YouTube.

finanznachrichten.de2 min
OCT 20
$BIVIMedAI 8/10

BioVie reports positive Phase 2 Parkinson’s data for bezisterim

BioVie Inc. reported that its experimental Parkinson's drug, bezisterim, improved motor and non-motor symptoms in early-stage patients with higher inflammation, according to Phase 2 SUNRISE-PD trial results. In the subgroup of 28 patients, those treated with bezisterim showed improvement, while placebo patients worsened slightly. Across all 57 patients, 25% on bezisterim saw meaningful improvement versus 4% on placebo.

finance.yahoo.com2 min
OCT 20
$BIVIMedAI 8/10

BioVie reports positive bezisterim trial results in Parkinson’s

BioVie Inc. (BIVI) reported Phase 2 trial results for bezisterim in early-stage Parkinson’s patients. In a subgroup with high inflammation, bezisterim improved motor and non-motor scores versus placebo. Overall, bezisterim patients were 6.25x more likely to show meaningful improvement. Adverse events were lower in the treatment group. The trial enrolled untreated patients using a hybrid design. BioVie focuses on neurological and liver disease therapies.

investing.com2 min